latest
Clinical Articles

Phase II results for sustained release ranibizumab treatment of AMD indicate patients may only require two ophthalmic visits per year

Anti-VEGF treatment of exudative age-related macular degeneration has represented a paradigm shift in the medical management of the disease however, not all patients obtain the same benefit and the burden of potentially monthly injections  and ophthalmic visits can often reduce the effectiveness of the treatment.  In an effort to overcome some of these challenges, a […]

Read full story

Phase III results with novel anti-VEGF molecule suggest that choosing the right treatment for each patient may be challenging

Results from two clinical trials testing a new anti-VEGF molecule against ranibizumab (trade name Lucentis) suggest that clinicians will still need to balance overall efficacy and adverse effects of treatments against patient compliance with more frequent dosing.  A recent clinical study compared a new treatment, 2 mg abicipar pegol (a novel DARPin molecule) against 0.5mg […]

Read full story

***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***

EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH), valued at up to €2 million.  The Research Call seeks proposals from suitably qualified clinical investigators to address the current clinical uncertainty in respect of the medical management of sub-macular […]

Read full story

Related Clinical News